MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance.
- DOI
- 10.1038/s41418-026-01811-9
- Published
- 2026 Aug 14
- Container
- Cell death and differentiation
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41418-026-01811-9,
title = {MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance.},
author = {Sohier P and Raymond JH and Aktary Z and Zidi N and Araktingi L and Charoenchon N and Pisibon C and Caberia S and Pasmant E and Macagno N and Delmas V and Gaudy-Marqueste C and Steingrimsson E and Ballotti R and Petit V and Larue L},
year = {2026},
journal = {Cell death and differentiation},
doi = {10.1038/s41418-026-01811-9},
url = {https://doi.org/10.1038/s41418-026-01811-9}
}RIS
TY - JOUR TI - MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance. AU - Sohier P AU - Raymond JH AU - Aktary Z AU - Zidi N AU - Araktingi L AU - Charoenchon N AU - Pisibon C AU - Caberia S AU - Pasmant E AU - Macagno N AU - Delmas V AU - Gaudy-Marqueste C AU - Steingrimsson E AU - Ballotti R AU - Petit V AU - Larue L PY - 2026 JO - Cell death and differentiation DO - 10.1038/s41418-026-01811-9 UR - https://doi.org/10.1038/s41418-026-01811-9 ER -
APA
P, S., JH, R., Z, A., N, Z., L, A., N, C., C, P., S, C., E, P., N, M., V, D., C, G., E, S., R, B., V, P., & L, L. (2026). MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance.. Cell death and differentiation. https://doi.org/10.1038/s41418-026-01811-9
Source records
- pubmed · retrieved 2026-09-26T12:33:34.500Z